Patents Represented by Attorney, Agent or Law Firm Jeffrey N. Myers
-
Patent number: 6492342Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein a, b, X, Y, Z, R1, R2, and R3 are as defined herein. The compounds of formula I are antibacterial and antiprotozoal agents useful for treating various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I, to methods of treating bacterial and protozoal infections by administering the compounds of formula I, and to methods for preparing compounds of formula I.Type: GrantFiled: October 27, 2000Date of Patent: December 10, 2002Assignee: Pfizer Inc.Inventor: Takushi Kaneko
-
Patent number: 6479513Abstract: The present invention relates to the compound (+)-6-[amino-(6-chloro-pyridin-3-yl)-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-chloro-phenyl)-1-cyclopropylmethyl-1H-quinolin-2-one, pharmaceutically acceptable salts and solvates thereof, prodrugs thereof, and to the use of said compound for inhibiting abnormal cell growth, including cancer, in mammals. The invention also relates to methods useful in synthesizing the aforementioned compound.Type: GrantFiled: January 17, 2001Date of Patent: November 12, 2002Assignee: Pfizer Inc.Inventor: Bingwei V. Yang
-
Patent number: 6420536Abstract: The invention relates to a method of preparing compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial protozoa infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.Type: GrantFiled: November 18, 1999Date of Patent: July 16, 2002Assignee: Pfizer IncInventors: Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
-
Patent number: 6417229Abstract: The present invention relates to a method of using a compound of the formula (I): wherein A, X1, X2 and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.Type: GrantFiled: September 27, 2000Date of Patent: July 9, 2002Assignee: Pfizer IncInventors: Barbara G. Sahagan, Anabella Villalobos
-
Patent number: 6413971Abstract: The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2 and Z are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of using said compounds in the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: May 19, 1999Date of Patent: July 2, 2002Assignee: Pfizer IncInventors: Lee Daniel Arnold, Mikel Paul Moyer, Susan Beth Sobolov-Jaynes
-
Patent number: 6410297Abstract: The present invention relates to avian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to avian cell lines which have been engineered to support the growth and productive infection of recombinant Marek's Disease Virus at high titers. The present invention relates a process for the preparation of Marek's Disease Virus in quantities suitable for vaccine purposes.Type: GrantFiled: November 19, 1999Date of Patent: June 25, 2002Assignee: Pfizer IncInventors: Sing Rong, Michael G. Sheppard
-
Patent number: 6407074Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.Type: GrantFiled: February 16, 2000Date of Patent: June 18, 2002Assignee: Pfizer IncInventors: Brian Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
-
Patent number: 6395733Abstract: The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification.Type: GrantFiled: November 9, 1999Date of Patent: May 28, 2002Assignee: Pfizer IncInventors: Lee Daniel Arnold, Mikel P. Moyer, Susan B. Sobolov-Jaynes
-
Patent number: 6380214Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein Z, X, X1, R1, R2 and R3 are as defined herein as it relates to pharmaceutical compositions containing the above compounds for the treatment of disorders mediated by angiogenesis in mammals by administration of the above compounds.Type: GrantFiled: April 17, 2000Date of Patent: April 30, 2002Assignee: Pfizer Inc.Inventors: Thomas George Gant, Mark Carl Noe
-
Patent number: 6376526Abstract: An antifungal compound of formula (I): or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R1 is phenyl subsituted with 1 to 3 substituents each independently selected from halo and CF3; R2 is (hydroxy)C1-C4 alkyl, CONH2, S(O)m(C1-C4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF3; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C1-C4 alkyl or (C1-C4 alkoxy)methyl.Type: GrantFiled: December 1, 1999Date of Patent: April 23, 2002Assignee: Pfizer Inc.Inventors: Andrew Simon Bell, Peter Thomas Stephenson
-
Patent number: 6335344Abstract: The present invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts thereof, wherein R1-R4 and Z are as defined herein. The compounds of formula (I) are useful as antiproliferative agents. The invention further relates to pharmaceutical compositions and methods of treating hyperproliferative disorders such as cancer, using such compounds.Type: GrantFiled: September 29, 1999Date of Patent: January 1, 2002Assignee: Pfizer Inc.Inventor: Rodney C. Schnur
-
Patent number: 6329397Abstract: A compound of the formula wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S), COX-2 inhibitors and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.Type: GrantFiled: August 12, 1999Date of Patent: December 11, 2001Assignee: PfizerInventors: Kim F. McClure, Mark C. Noe, Michael A. Letavic, Louis S. Chupak
-
Patent number: 6323041Abstract: This invention relates to novel nucleic acid sequences encoding three novel human phosphodiesterase (hPDE IV) isozymes. It also relates to polypeptides encoded by such sequences. This invention also relates to an assay method for detecting the presence of such novel isozymes in human cells, and to a method of identifying compounds or other substances that inhibit or modify the activity of such isozymes.Type: GrantFiled: June 7, 1995Date of Patent: November 27, 2001Assignee: Pfizer Inc.Inventors: Douglas A. Fisher, Michael D. Robbins
-
Patent number: 6313312Abstract: Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.Type: GrantFiled: December 20, 1999Date of Patent: November 6, 2001Assignee: Pfizer INCInventors: Bernard Joseph Banks, Robert James Crook, Stephen Paul Gibson, Graham Lunn, Alan John Pettman
-
Patent number: 6277860Abstract: This invention provides a compound of formula (I): or pharmaceutically acceptable salts thereof, wherein X1 and X2 are C or N, respectively; R1 and R2 are independently phenyl optionally substituted with a hydroxy group with proviso that X1 and X2 are not simultaneously C or N, when X1 is N, R1 is absent, and when X2 is N, R2 is absent; R3 is methyl or hydroxymethyl; R4 is formyl, hydroxymethyl or hydroxy C3-6 alkenyl; R5 is hydroxy, C3-6 alkenyl or hydroxy C3-6 alkenyl; or R4 and R5, together with the carbon atoms in the furopyridine ring to which they are attached, may form the following ring (to be fused with the furopyridine ring): with the proviso that when R3 is methyl and R5 is 2-buten-2-yl, X2 is not N. These compounds and pharmaceutical compositions containing such compounds are useful for treating infectious diseases caused by bacteria.Type: GrantFiled: October 29, 1999Date of Patent: August 21, 2001Assignee: Pfizer IncInventors: Yutaka Sugie, Akemi Sugiura, Nobuji Yoshikawa, Susan J. I Truesdell, John W. Wong
-
Patent number: 6270768Abstract: This invention relates to methods of preparing compounds of Formula 1: and to pharmaceutically acceptable salts and solvates thereof, and to methods for preparing same. The compounds of Formula 1 are antibacterial agents that may be used to treat various bacterial and protozoal infections, and may also be used to treat cancer. The invention also relates to pharmaceutical compositions comprising the compounds of Formula 1, and to methods of treating sbacterial and protozoal infections by administering compounds of Formula 1.Type: GrantFiled: January 26, 2000Date of Patent: August 7, 2001Assignee: Pfizer IncInventors: Thomas N. O'Connell, Brook K. Morse, Hamish Alastair Irvine McArthur, John Philip Dirlam
-
Patent number: 6248719Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The compounds of formula 1 are useful as antibiotic agents. The invention further relates to pharmaceutical compositions and methods of treating bacterial infection using such compounds, and to methods of making the compounds of formula 1.Type: GrantFiled: February 18, 2000Date of Patent: June 19, 2001Assignee: Pfizer IncInventor: Yong-Jin Wu
-
Patent number: 6225318Abstract: This invention relates to certain 4-aminoquinazoline derivatives of the formula and their pharmaceutically acceptable salts wherein R1, Q1, m, n, and Z are defined as in the specification. The compounds of formula I and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative disorders and conditions in mammals.Type: GrantFiled: November 26, 1999Date of Patent: May 1, 2001Assignee: Pfizer IncInventors: Susan B. Sobolov-Jaynes, Lee D. Arnold
-
Patent number: 6194438Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula I and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of Formula I to said mammal.Type: GrantFiled: December 2, 1999Date of Patent: February 27, 2001Assignee: Pfizer Inc.Inventors: Bingwei V. Yang, Joseph P. Lyssikatos